|
|
| | PantoprazoleSodiumSesquihydrate Basic information |
| Product Name: | PantoprazoleSodiumSesquihydrate | | Synonyms: | 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-, sodium salt, hydrate (2:3);Unii-6871619Q5x;6-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt hydrate (2:2:3);SKF-96022 SODIUM HYDRATE;Pantoprazole sodium sesquihydrate CRS;Pantoprazole for system suitability CRS;BY1023 (sodium hydrate);Pantoprazole Sodium sesqui hydrate- IP/BP/USP | | CAS: | 164579-32-2 | | MF: | C16H18F2N3NaO5S | | MW: | 425.38 | | EINECS: | 1312995-182-4 | | Product Categories: | | | Mol File: | 164579-32-2.mol |  |
| | PantoprazoleSodiumSesquihydrate Chemical Properties |
| storage temp. | 4°C, protect from light | | solubility | Freely soluble in water and in ethanol (96 per cent), practically insoluble in hexane. | | form | Solid | | color | White to off-white | | Major Application | pharmaceutical (small molecule) | | InChI | 1S/C16H16F2N3O4S.Na.H2O/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;;/h3-7,15-16,21H,8H2,1-2H3;;1H2/q-1;+1; | | InChIKey | QHNXIKDJFYGZTL-UHFFFAOYSA-N | | SMILES | [Na+].FC(F)Oc1cc2c(cc1)[N-]C(N2)[S](=O)Cc3nccc(c3OC)OC.O |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | nwg | | HS Code | 2933399090 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | PantoprazoleSodiumSesquihydrate Usage And Synthesis |
| Chemical Properties | White or almost white powder. | | Uses | Pantoprazole Sodium Hydrate is a metabolite of Pantoprazole Sodium Salt which is an antiulcerative. Gastric pump inhibitor. The free acid, Pantoprazole is a prodrug used in the treatment of acid related disorders and Helicobacter pylori infections. | | Uses | Treatment of various acid-related gastrointestinal diseases, including acute erosive esophagitishealing and maintenance, treatment of hypersecretory
conditions, Zollinger-Ellison Syndrome (ZES), and eradication
of Helicobacter pylori infection. | | Brand name | Protonix (Wyeth). | | in vivo | Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin[1].
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats[4].
| Animal Model: | Mice bearing MCF-7 or A431 xenografts[1] | | Dosage: | 200 mg/kg | | Administration: | IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.) | | Result: | Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin.
There is no effect on growth delay alone.
|
|
| | PantoprazoleSodiumSesquihydrate Preparation Products And Raw materials |
|